Cardiovascular morbidity and mortality as a confounder of prognosis in thyroid cancer

Abstract

Thyroid cancer (TC) constitutes more than 95% of all endocrine tumors. Differentiated thyroid carcinoma (DTC), which includes the papillary and follicular types, constitutes about 90% of all TCs and 2.1% of all cancers. The incidence of DTC has increased significantly worldwide, with papillary cancer leading this trend and being the most prevalent. Whereas the prognosis of patients with DTC is generally favorable, with the overall 5-year survival rate reaching up to 95%, long-term follow-up also discloses increased propensity for cardiovascular and cerebrovascular risk factors, morbidity, and mortality. Cardiovascular events are linked to TC particularly in subjects aged 45 years or more. The present review and analysis seek to highlight the significance of cardiovascular disease in the overall prognosis among TC survivors and explore potential mechanisms which might link treatment choices in DTC to cardiovascular risk and disease outcome.

Keywords

Thyroid cancer / cardiovascular morbidity / cardiovascular mortality / cardiovascular risk factors

References

[1] Davies L.Current thyroid cancer trends in the United States.JAMA Otolaryngol Head Neck Surg2014;140:317-22

[2] La Vecchia C,Bosetti C.Thyroid cancer mortality and incidence: a global overview.Int J Cancer2015;136:2187-95

[3] Konturek A,Stopa M.Trends in prevalence of thyroid cancer over three decades: a retrospective cohort study of 17,526 surgical patients.World J Surg2016;40:538-44 PMCID:PMC4746222

[4] Kitahara CM.The changing incidence of thyroid cancer.Nat Rev Endocrinol2016;12:646-53

[5] Haugen BR,Bible KC.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer.Thyroid2016;26:1-133 PMCID:PMC4739132

[6] Filetti S,Hartl D.Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol2019;30:1856-83

[7] Mazzaferri EL.Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients.Am J Med1981;70:511-8

[8] Hall P,Holm LE.Mortality in patients treated for hyperthyroidism with iodine-131.Acta Endocrinol (Copenh)1993;128:230-4

[9] Franklyn JA,Sheppard MC,Boyle P.Mortality after the treatment of hyperthyroidism with radioactive iodine.N Engl J Med1998;338:712-8

[10] Franklyn JA,Maisonneuve P.Thyroid function and mortality in patients treated for hyperthyroidism.JAMA2005;294:71-80

[11] Metso S,Huhtala H,Oksala H.Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism.J Clin Endocrinol Metab2007;92:2190-6

[12] Collet TH,Bauer DC.Subclinical hyperthyroidism and the risk of coronary heart disease and mortality.Arch Intern Med2012;172:799-809 PMCID:PMC3872478

[13] Sawin CT,Wolf PA.Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.N Engl J Med1994;331:1249-52

[14] Klein Hesselink EN,de Bock GH.Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study.J Clin Oncol2013;31:4046-53

[15] Yang L,Sakamoto N.Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer.J Clin Oncol2013;31:468-74

[16] Izkhakov E,Barchana M.Long-term all-cause mortality and its association with cardiovascular risk factors in thyroid cancer survivors: an Israeli population-based study.BMC Cancer2020;20:892 PMCID:PMC7500542

[17] Mercuro G,Bina A.Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring.J Clin Endocrinol Metab2000;85:159-64

[18] Shargorodsky M,Gavish D,Harpaz D.Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma.Thyroid2006;16:381-6

[19] Biondi B,Carella C.Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.J Clin Endocrinol Metab1993;77:334-8

[20] Fazio S,Carella C.Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade.J Clin Endocrinol Metab1995;80:2222-6

[21] Taillard V,Oudot C.Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.Clin Endocrinol (Oxf)2011;75:709-14

[22] Gazdag A,Erdei A.Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer.J Endocrinol Invest2015;38:133-42

[23] Abdulrahman RM,Hoftijzer HC.Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma.Thyroid2011;21:471-6

[24] Abonowara A,Sapp JL.Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer.Clin Invest Med2012;35:E152-6

[25] Horne MK 3rd,Rosenfeld KG.Is thyroid hormone suppression therapy prothrombotic?.J Clin Endocrinol Metab2004;89:4469-73

[26] Pajamäki N,Hakala T.Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.Clin Endocrinol (Oxf)2018;88:303-10

[27] Suh B,Park Y.Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study in Korea.Eur J Endocrinol2019;180:11-20

[28] Izkhakov E,Barchana M,Stern N.Long-term cardiovascular and cerebrovascular morbidity in Israeli thyroid cancer survivors.Endocr Connect2019;8:398-406 PMCID:PMC6454303

[29] Zoltek M,Hedman C,Nordenvall C.Cardiovascular Incidence in 6900 Patients with Differentiated Thyroid Cancer: a Swedish Nationwide Study.World J Surg2020;44:436-41

[30] Klein I.Thyroid disease and the heart.Curr Probl Cardiol2016;41:65-92

[31] Blackburn BE,Rowe K.Aging-related disease risks among young thyroid cancer survivors.Cancer Epidemiol Biomarkers Prev2017;26:1695-704 PMCID:PMC5903447

[32] Toulis KA,Gkoutos G,Boelaert K.Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease.Clin Endocrinol (Oxf)2019;91:323-30

[33] Park J,Ganz PA.Risk factors for cardiovascular disease among thyroid cancer survivors: findings from the Utah cancer survivors study.J Clin Endocrinol Metab2018;103:2468-77 PMCID:PMC6915829

[34] Lin CY,Lo YC.Association between radioiodine treatment for thyroid cancer and risk of stroke.Head Neck2017;39:2311-8

[35] Kim KJ,Kim JY.Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: a nationwide cohort study.Ann Transl Med2020;8:1235 PMCID:PMC7607121

[36] Kim B.Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate.Thyroid2008;18:141-4

[37] Iacobellis G,Zappaterreno A,Leonetti F.Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women.Clin Endocrinol (Oxf)2005;62:487-91

[38] Roos A,Links TP,Wolffenbuttel BH.Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects.J Clin Endocrinol Metab2007;92:491-6

[39] Izkhakov E,Barnes S,Stern N.Body composition, resting energy expenditure, and metabolic changes in women diagnosed with differentiated thyroid carcinoma.Thyroid2019;29:1044-51 PMCID:PMC6707037

[40] Wolf M,Kreymann G.Body composition and energy expenditure in thyroidectomized patients during short-term hypothyroidism and thyrotropin-suppressive thyroxine therapy.Eur J Endocrinol1996;134:168-73

[41] Ito M,Kang S.Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients.Eur J Endocrinol2015;173:333-40

[42] Lovejoy JC,Bray GA.A paradigm of experimentally induced mild hyperthyroidism: effects on nitrogen balance, body composition, and energy expenditure in healthy young men.J Clin Endocrinol Metab1997;82:765-70

[43] Lebon V,Petersen KF.Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle.J Clin Invest2001;108:733-7 PMCID:PMC209375

[44] Sugitani I.Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma?.J Clin Endocrinol Metab2010;95:4576-83